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Abstract We studied the ability of cytokines to activate the 
nuclear transcription factor NF-KB in human pancreatic islets 
and the putative role of NF-KB for cytokine-induced NO 
production. Brief exposure (20 min) of human islets of 
Langerhans to a combination of interleukin-1!3 + interferon- 
y + tumor necrosis factor-a induced a 2.6-fold increase in 
nuclear NF-KB activity in gel shift analysis. This increase was 
prevented by the NF-KB inhibitor, pyrrolidine dithiocarbamate 
(PDTC), which also counteracted NO production by human 
islets exposed for 14 h to the cytokine combination. High 
concentrations of interleukin-lb alone (150 and 250 U/ml) 
increased NF-KB nuclear binding but failed to induce NO 
formation in human islets. The present data are the first to 
demonstrate that cytokines activate NF-KB in primary adult 
human pancreatic islets and suggest that activation of NF-KB 
may be a necessary hut not suffbzient signal for cytokine-induced 
iNOS expression in human islets of Langerhans. 
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1. Introduction 
Cytokines may be mediators of p-cell damage in insulin 
dependent diabetes mellitus (IDDM) [l]. These inflammatory 
proteins bind to islet cell receptors and induce a cascade of 
signals, culminating with the transcription of the inducible 
form of nitric oxide synthase (iNOS) and NO production 
[2,3]. The nature of these intracellular signals remains to be 
clarified. At high concentrations, NO has many detrimental 
effects to the p-cells, including inhibition of the mitochondrial 
enzyme aconitase and DNA damage [4,5]. Based on these 
data, a central role has been proposed for NO in immune- 
mediated P-cell death in early IDDM [6]. 
NF-KB is a dimeric transcription factor consisting of 
homo- or heterodimers of the subunits ~50 and/or ~65 (for 
a recent review see [7]). In its inactivated state it stays in the 
cytosol bound to an inhibitory subunit, IKB. The signal(s) 
leading to activation of NF-KB remains to be identified, but 
the fact that the antioxidant pyrrolidine dithiocarbamate 
(PDTC) blocks NF-KB activation suggests that cytokine-in- 
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duced production of free oxygen radicals may play a role in 
NF-KB activation [8]. Upon activation, IKB is released and 
proteolytically degraded, whereas the p5O/p65 dimer is trans- 
ported to the nucleus. In the nucleus the dimer binds to NF- 
KB binding sites in promoter regions of specific genes, affect- 
ing their transcription. The promoter of the murine macro- 
phage iNOS gene contains several binding motifs for tran- 
scription factors, including two NF-KB binding sites, 10 IRE 
(Interferon-y responsive element), two ISRE (IFN-a stimu- 
lated response elements), two AP-1, etc. An analysis of the 
putative human iNOS promoter revealed 66% identity to the 
murine iNOS gene and consensus sequences for three IRE and 
one NF-KB binding site [9]. 
It has previously been shown that IL-lb activates NF-KB in 
the rodent insulinoma cell line RINmSF [lo] and that this is a 
necessary step in the induction of iNOS mRNA [1 l-131. It is 
noteworthy that while IL-lp alone is enough to induce iNOS 
transcription and NO formation in rat islets, it is necessary to 
use a combination of IL-lj3 + IFN-y + TNF-a to achieve 
iNOS mRNA expression and NO formation in human islets 
of Langerhans [14]. Thus, it remains unclear whether NF-KB 
is also of relevance for NO production by human pancreatic 
islets. The present study evaluated the role for NF-KB activa- 
tion in NO formation by human islets of Langerhans. 
2. Materials and methods 
2.1. Materials 
Human recombinant IL-lb (bioactivity 50 U/ng) was kindly do- 
nated by Dr K. Bendtzen (Laboratory of Medical Immunology, Rigs- 
hospitalet, Copenhagen, Denmark). Recombinant human IFN-y and 
murine TNF-a (bioactivity 6.7 and 10 Ulng, respectively) were pur- 
chased from AMS Biotechnology (Sweden). The cytokine concentra- 
tions used in the present experiments are based upon previous data 
obtained in rat [15] and human pancreatic islets [14]. Double stranded 
oligomers for EMSA were produced by Dr. J. Seibt (Dept. of Immu- 
nology, Uppsala University, Uppsala, Sweden) and labelled with a 
Megaprime labelling kit (Amersham International, Aylesbury, UK). 
Culture medium RPMI-1640 (containing 0 or 11 mM glucose) and 
fetal calf serum were purchased from Northumbria Biologicals (Ir- 
vine, UK). All other chemicals of analytical grade were obtained 
from E. Merck (Darmstadt, Germany) or Sigma. 
2.2. Methods 
Human islets of Langerhans were isolated from 14 heart-beating 
organ donors at the Central Unit of the B-Cell Transplant, Brussels 
as described elsewhere [16]. The age of the donors was 38 f 4 years 
(range 15-54 years). Aliquots of the preparations were examined by 
electron microscopy (n = 12), indicating 5 + 1% dead cells and 1% 
exocrine cells. The prevalence of insulin- and glucagon-positive cells 
was determined by light microscopical examination of immuno histo- 
chemically stained islets, showing 48 f 5”/0 insulin-positive cells and 
9 t 2% glucagon-positive cells. After isolation islets were cultured in 
Brussels for 2-18 days (7f 1 days) [16], before being sent by air to 
Uppsala. Rat islets were isolated from adult male Sprague Dawley 
rats. Both human and rat islets were cultured free-floating in RPMI- 
0014-5793/96/$12.00 0 1996 Federation of European Biochemical Societies. All rights reserved 
PIISOOl4-5793(96)00337-7 
M. Flodstriim et al.IFEBS Letters 385 (1996) 46 
1640 medium containing 10% (v/v) fetal calf serum, benzylpenicillin 
(100 U/ml), streptomycin (0.1 mg/ml) and 5.6 or 11 mM glucose (hu- 
man and rat islets, respectively) before the experiments were per- 
formed. During this period medium was changed every second day. 
After 46 days in culture, human islets were exposed to IL-lp alone 
(150 or 250 U/ml) or to the combination of IL-lb (50 U/ml) + TNF-c( 
(1000 U/ml) + IFN-y (1000 U/ml) whereas rat islets were exposed to 
IL-l!3 (50 U/ml). After 14 h of culture medium was retrieved for 
nitrite determination using the Greiss reagent as previously described 
[12], and islet DNA contents measured [14]. In some experiments hu- 
man and rat islets were pre-treated for 1 h with PDTC before expo- 
sure to cytokines. Note that PDTC was also present during the 14 h 
exposure to cytokines. PDTC was previously found to interact with 
the nitrite assay, reducing the nitrite values by 20% 1111. Thus all 
experiments where PDTC was added were corrected accordingly. 
For the electrophoretic mobility shift assay (EMSA) 1000-1500 hu- 
man islets were exposed to cytokines for 20 min, washed with cold 
PBS and nuclear protein fractions extracted (for a detailed description 
see [lo]). Note that the extreme shortage of adult human islets much 
limits the number of experiments that can be performed with these 
cells. In some experiments PDTC was added for 1 h before cytokine 
exposure. Protein concentrations were determined using the Bradford 
reagent. For the EMSA a double-stranded 26 mer oligonucleotide 
containing the KB binding site; 5’-AGCTTCAGAGGGGACTTTCC- 
GAGAGG, was used. A lOOO-fold excess of non-labelled oligonucleo- 
tide was used as a negative control. The oligonucleotide was labelled 
with [32P]dCTP using the Megaprime labelling kit and extracted once 
with an equal volume of phenoYchloroform/isoamyl acohol (25:25:1, 
v/v). Before incubation with the oligonucleotide, nuclear fractions (55 
10 pg) were denatured with formamide (27%). The fractions were then 
allowed to react with the nucleotide for 30 min at room temperature 
in a solution containing 10 mM Tris (pH 7.5), 0.2% deoxycholic acid, 
40 mM NaCl, 1 mM EDTA, 1 mM B-mercaptoethanol, 4% glycerol, 
2 pg polydeoxyinosinic acid and 0.1 ng DNA (14000 cpm). The sam- 
ples were then separated on 5% non-denaturing polyacrylamide gels in 
0.5 x TBE. Band intensities were quantified by densitometric scanning 
with a Quick Scan Jr densitometer (Helena Laboratories, Beaumont, 
TX) and values corrected for the amount of loaded protein. 
Growing RINmSF cells were trypsinized and subcultured in RPM1 
1640 supplemented as described above for rat islet culture [11,12]. 
When reaching 60-80% confluence, cells were pre-treated with 
PDTC for 30 min before cytokine exposure. After 6 h culture, med- 
ium was taken and nitrite measured as mentioned above. 
Data are presented as mean f S.E.M. Results were compared using 
Student’s unpaired or paired t-test. When multiple comparisons were 
performed, ANOVA with corrections by the Bonferroni method was 
used. Experimental results obtained from each human islets prepara- 
tion (i.e. islets obtained from one donor) were considered as one 
individual observation, even when experiments were performed in 
duplicates of triplicates. 
3. Results and discussion 
To evaluate the role for NF-KB in the human islet response 
to cytokines, in seven separate experiments islets were exposed 
to IL-1B (50 U/ml) + IFN-?/ (1000 U/ml) + TNF-a (1000 U/ 
ml) (7) for 20 min and NF-KB binding activity was determined 
by EMSA. Densitometric scanning of the auto radiographs 
revealed a 2.6-fold increase in nuclear NF-KB binding in islets 
exposed to the cytokine combination (n = 7, P < 0.05, see 
representative gel in Fig. 1; lanes 1,4, and lanes 556). In 
two separate experiments islets were exposed to IL-l/3 alone 
(150 and 250 U/ml) or to a combination of cytokines (same as 
above) for 20 min. A clear increase in NF-KB binding was 
seen in both experiments using IL-ID, but the NF-KB induc- 
tion was less marked than that observed with the three cyto- 
kines (Fig. 1). As previously described [15,17] human islet 
exposure to IL-1B alone for 14 h failed to induce nitrite for- 
mation (pmol/ng DNA per h; mean of 2 similar experiments; 
control, 6.6; IL-l@ (150 U/ml), 2.2; IL-l!3 (250 U/ml), 2.9; IL- 
1 B (50 U/ml) + IFN-71 (1000 U/ml) + TNF-a (1000 U/ml), 
123456789 
Fig. 1. EMSA showing nuclear NF-KB binding activity in human 
pancreatic islets exposed to cytokines and/or PDTC. Islets were ex- 
posed to IL-1B (150 or 250 U/ml) alone or to the combination of 
IL-ID (50 U/ml) + IFN-y (1000 U/ml) + TNF-a (1000 U/ml) for 20 
min and then retrieved for EMSA as described in section 2. In 
some experiments islets were pre-treated for 1 h with PDTC (100 
PM) before cytokine exposure. Lanes: 1, control; 2, IL-ID (150 UI 
ml); 3, IL-1B (250 U/ml); 4, IL-lb + IFN-y+ TNF-a; 5, control; 
6, IL-1B + IFN-y + TNF-o; 7, PDTC; 8, PDTC + IL-IS + IFN- 
y + TNF-a; 9, negative control using lOOO-fold excess of non-la- 
belled oligonucleotide. The autoradiograph is representative for 2 se- 
parate experiments. 
11.6). These findings indicate that the combination of cyto- 
kines induces NF-KB in human islets of Langerhans and that, 
although to a lesser extent, this is also true for IL-1B alone. 
Considering that the motif for NF-KB binding is present in 
the human iNOS promoter region [9], it is possible that this 
transcription factor may play a role in the cytokine-induced 
iNOS transcription in human islets of Langerhans. To further 
investigate this hypothesis, blockage of NF-KB activation by 
PDTC in human islets was tested. Firstly, in two separate 
experiments human islets were pre-treated with 100 uM 
PDTC for 1 h and subsequently exposed to IL-lb (50 UI 
ml) + IFN-)I (1000 U/ml) + TNF-a (1000 U/ml) for 20 min 
before extraction of nuclear proteins for EMSA (Fig. 1; lanes 
558). It was found that PDTC completely inhibited cytokine- 
induced NK-KB activation. Secondly, in six separate experi- 
ments human islets were treated with PDTC (50 or 100 PM) 
for 1 h [11,12] before exposure to the three cytokines. After 14 
h incubation, medium was retrieved for nitrite determination 
(Fig. 2). Control islets and islets exposed to PDTC alone, 
produced low and similar levels of nitrite. When exposed to 
cytokines, medium nitrite levels increased 56-fold (P < 0.001 
vs. control). Both concentrations of PTDC were able to block 
most of the cytokine-induced increase in NO production 
(P < 0.001 vs. islets exposed to cytokines alone; P > 0.05 
vs. controls). 
We have previously shown that PDTC prevents IL-lb-in- 
duced iNOS mRNA expression and nitrite formation in 
RINmSF cells [11,12], a finding recently reproduced by 
Kwon and co-workers [13]. In order to investigate the role 
for NF-KB in primary adult rat islets, in 334 experiments 
rat islets pre-treated with 50 or 100 uM PDTC for 1 h were 
exposed to IL-1B (25 U/ml). After 14 h exposure to IL-ID 
and/or PDTC, nitrite accumulation to the medium was meas- 
ured. Low and similar nitrite levels were found in medium 
from control islets (0.33 + 0.10 pmol/islet per h) and islets 
cultured with PDTC alone (0.17 f 0.06 and 0.20 + 0.12 pmol/ 
islet per h, for islets treated with 50 and 100 uM PDTC, 
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Fig. 2. PDTC effects on cytokine-induced nitrite formation by hu- 
man islets of Langerhans. Islets were pre-treated with PDTC for 1 h 
before exposure to cytokines and/or PDTC. After 14 h culture med- 
ium nitrite accumulation was determined as described in section 2. 
Results are presented as mean f S.E.M. of 6 separate experiments. 
‘P < 0.001 vs islets exposed to cytokines, ANOVA. 
respectively). Islets exposed to IL-lb produced 5 times more 
nitrite than control islets (1.65 f 0.21 pmol/islet per h, P<O.Ol 
vs. control islets). Pre-incubation with PDTC significantly de- 
creased this cytokine-induced increase in nitrite levels 
(0.23 & 0.03 and 0.33 f 0.13 pmol/islet per h for islets treated 
with 50 and 100 pM PDTC, respectively, P < 0.05 vs. islets 
exposed to cytokines). In order to test whether PDTC could 
also prevent nitrite production by a combination of three 
cytokines in rodent insulin-producing cells, RIN cells were 
pre-treated with 50 pM PDTC for 30 min and then exposed 
to IL-lb (25 U/ml) or IL-lb (25 U/ml) + IFN=y (1000 U/ 
ml) + TNF-cx (1000 U/ml) and/or PDTC. After 6 h, nitrite 
accumulation into the medium was measured. Control cells 
and cells incubated with PDTC alone produced low and simi- 
lar levels of nitrite (control cells, 30 f 18 pmol/106 cells per h; 
PDTC treated cells, 49 f 30 pmol/106 cells per h). IL-lp alone 
and the three cytokines induced a 30- and 70-fold increase, 
respectively, in nitrite levels compared to control cells 
(P < 0.01 for both comparisons, data not shown). Both of 
these increases were completely blocked in cells pre-treated 
with PDTC (P < 0.01 vs. cells exposed to cytokines alone 
and P > 0.05 vs. control islets). 
These data confirm our previous observations that PDTC 
prevents cytokine-induced iNOS expression and NO forma- 
tion in RIN cells [6], and implicate the activation of the tran- 
scription factor NF-KB as a necessary step in the signal-trans- 
duction for NO production in rodent insulin-producing cells. 
The above-described results also indicate that activation of 
NF-KB is needed for the induction of iNOS and NO produc- 
tion in adult human pancreatic islets. To our knowledge, this 
is the first demonstration for such a role of NF-KB in primary 
adult human cells. It is unclear why human islet cells need 
three cytokines for the induction of iNOS whereas rodent islet 
cells require only IL-lp. However, it is conceivable that in 
human islets additional cytosolic signal(s) besides NF-KB are 
required for iNOS expression, as compared to rodent islets. 
Indeed, NF-KB activation may be necessary but not sufficient 
for cytokine-induced NO production in human islets, as 
judged by; (a) the ability of PDTC to block NF-KB activation 
and nitrite formation; (b) the observation that IL-lfl alone 
activates NF-KB but fails to induce NO formation. 
NF-KB exists preformed in the cytoplasm until its activation 
[7]. In this context, the observation that the protein synthesis 
inhibitor cycloheximide prevents cytokine-induced iNOS 
mRNA expression in several cell types [9], including insulin- 
producing cells [12,18], suggests that other factor(s) besides 
NF-KB is (are) also important for iNOS induction. Recent 
data suggest that interferon regulatory factor-l (IRF-I), a 
transcription factor which requires de novo synthesis after 
cytokine exposure, may play a role for IL-lb-induced iNOS 
expression in rat islets [19]. Considering that IFN-y is neces- 
sary for iNOS mRNA expression in human islets [14] and that 
there are binding sites for IRF-1 both in the murine and in the 
human iNOS promoter [9], it is conceivable that both species 
need activation of NF-KB and IRF-1 (and possibly other fac- 
tor(s)) to induce the iNOS gene. Further characterisation of 
the molecular regulation of human iNOS may open new alter- 
natives for an early therapeutic intervention to prevent P-cell 
destruction in IDDM. 
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